Obstetrics & GynaecologyObstetrics & Gynaecologyhttp://hdl.handle.net/2262/832015-03-31T18:08:06Z2015-03-31T18:08:06ZPoor glycated haemoglobin and adverse pregnancy outcomes in Type 1 and Type 2 Diabetes mellitus - Systematic review of observational studies.MURPHY, DEIRDREhttp://hdl.handle.net/2262/731952015-02-14T03:03:02Z2006-01-01T00:00:00ZPoor glycated haemoglobin and adverse pregnancy outcomes in Type 1 and Type 2 Diabetes mellitus - Systematic review of observational studies.
MURPHY, DEIRDRE
PUBLISHED
2006-01-01T00:00:00ZPre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening.O'LEARY, JOHN JAMESO'TOOLE, SHARONMARTIN, CARASHEILS, ORLANORRIS, LUCY ANGELAFINN, STEPHENhttp://hdl.handle.net/2262/727372015-02-06T13:12:31Z2013-01-01T00:00:00ZPre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening.
O'LEARY, JOHN JAMES; O'TOOLE, SHARON; MARTIN, CARA; SHEILS, ORLA; NORRIS, LUCY ANGELA; FINN, STEPHEN
Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used. The cytotoxic effect of MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) alone or in combination with cisplatin was determined using high content screening. Protein expression was examined using immunohistochemistry and ELISA. Co-incubation of cisplatin and an MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) resulted in significantly greater cytotoxicity as compared to either treatment alone in a cisplatin resistant MMP-9 overexpressing cell line; A2780cis. In addition, pre-incubating with MMP-9i prior to cisplatin further enhances the cytotoxic effect. No significant difference was observed in MMP-9 protein in tissue but a trend towards increased MMP-9 was observed in recurrent serum. We propose that MMP-9/MMP-2i may be utilized in the treatment of recurrent/chemoresistant ovarian cancers that overexpress MMP-9 mRNA but its role in vivo remains to be evaluated.
PUBLISHED
2013-01-01T00:00:00ZPopulation-Based Study of Smoking Behaviour throughout Pregnancy and Adverse Perinatal Outcomes.MURPHY, DEIRDREhttp://hdl.handle.net/2262/723132014-12-02T03:04:12Z2013-01-01T00:00:00ZPopulation-Based Study of Smoking Behaviour throughout Pregnancy and Adverse Perinatal Outcomes.
MURPHY, DEIRDRE
There has been limited research addressing whether behavioural change in relation to smoking is maintained throughout pregnancy and the effect on perinatal outcomes. A cohort study addressed lifestyle behaviours of 907 women who booked for antenatal care and delivered in a large urban teaching hospital in 2010-2011. Adverse perinatal outcomes were compared for "non-smokers", "ex-smokers" and "current smokers". Of the 907 women, 270 (30%) reported smoking in the six months prior to pregnancy, and of those 160 (59%) had stopped smoking and 110 (41%) continued to smoke at the time of the first antenatal visit. There was virtually no change in smoking behaviour between the first antenatal visit and the third trimester of pregnancy. Factors associated with continuing to smoke included unplanned pregnancy (OR 1.9; 95% CI 1.3, 2.9), alcohol use (OR 3.4; 95% CI 2.1, 6.0) and previous illicit drug use (OR 3.6; 95% CI 2.1, 6.0). Ex-smokers had similar perinatal outcomes to non-smokers. Current smoking was associated with an average reduction in birth weight of 191 g (95% CI -294, -88) and an increased incidence of intrauterine growth restriction (24% versus 13%, adjusted OR 1.39 (95% CI 1.06, 1.84). Public Health campaigns emphasise the health benefits of quitting smoking in pregnancy. The greatest success appears to be pre-pregnancy and during the first trimester where women are largely self-motivated to quit.
PUBLISHED
2013-01-01T00:00:00ZA prospective cohort study of alcohol exposure in early and late pregnancy within an urban population in IrelandBARRY, JOSEPHMURPHY, DEIRDREhttp://hdl.handle.net/2262/704592014-07-23T02:02:39Z2014-01-01T00:00:00ZA prospective cohort study of alcohol exposure in early and late pregnancy within an urban population in Ireland
BARRY, JOSEPH; MURPHY, DEIRDRE
Most studies of alcohol consumption in pregnancy have looked at one time point only, often relying on recall. The aim of this longitudinal study was to determine whether alcohol consumption changes in early and late pregnancy and whether this affects perinatal outcomes. We performed a prospective cohort study, conducted from November 2010 to December 2011 at a teaching hospital in the Republic of Ireland. Of the 907 women with a singleton pregnancy who booked for antenatal care and delivered at the hospital, 185 (20%) abstained from alcohol in the first trimester but drank in the third trimester, 105 (12%) consumed alcohol in the first and third trimesters, and the remaining 617 (68%) consumed no alcohol in pregnancy. Factors associated with continuing to drink in pregnancy included older maternal age (30-39 years), Irish nationality, private healthcare, smoking, and a history of illicit drug use. Compared to pre-pregnancy, alcohol consumption in pregnancy was markedly reduced, with the majority of drinkers consuming ≤ 5 units per week (92% in first trimester, 72-75% in third trimester). Perhaps because of this, perinatal outcomes were similar for non-drinkers, women who abstained from alcohol in the first trimester, and women who drank in the first and third trimester of pregnancy. Most women moderate their alcohol consumption in pregnancy, especially in the first trimester, and have perinatal outcomes similar to those who abstain.
PUBLISHED
2014-01-01T00:00:00Z